Lessons from a failed γ-secretase Alzheimer trial

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• Gamma-secretase proteases are implicated in Alzheimer disease (AD) pathogenesis.
• A recent broad-spectrum gamma-secretase inhibitor trial in AD patients yielded negative results, impacting therapeutic research enthusiasm.

Purpose of the Study:

• To re-evaluate the therapeutic potential of gamma-secretase research in Alzheimer disease.
• To identify confounds in interpreting the negative drug trial outcome.
• To highlight critical knowledge gaps in gamma-secretase mechanisms and roles.

Main Methods:

• Analysis of existing scientific literature and drug trial data.
• Critical review of the physiological roles and pathological associations of gamma-secretase.
• Identification of confounding factors in the interpretation of clinical trial results.

Main Results:

• The negative outcome of the broad-spectrum inhibitor trial may be due to specific confounds, not necessarily a lack of therapeutic potential.
• Significant gaps exist in understanding the basic mechanisms and physiological functions of gamma-secretase.
• Existing data suggests that gamma-secretase research remains a vital area for AD therapeutic development.

Conclusions:

• Pessimism regarding gamma-secretase therapeutics for AD is unwarranted.
• Addressing knowledge gaps in gamma-secretase biology is crucial for future therapeutic strategies.
• Further investigation into selective gamma-secretase modulators is recommended.